Reviva Plans to Initiate Second Phase 3 Trial for Brilaroxazine in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy RVPH?
Source: Globenewswire
- FDA Feedback: The FDA recommended a second Phase 3 trial prior to NDA submission to generate additional efficacy and safety data, highlighting the potential of brilaroxazine in treating schizophrenia.
- Clinical Data: The existing data package demonstrates broad-spectrum efficacy in major symptom domains of schizophrenia across 790 subjects, with over 900 treated showing a generally well-tolerated safety profile, indicating strong market competitiveness.
- Trial Plans: Reviva plans to initiate the RECOVER-2 registrational trial in H1 2026, with a design similar to the completed RECOVER Phase 3 trial, aimed at further validating the drug's efficacy and safety.
- Funding Needs: The initiation of the new trial is contingent on sufficient financing, with Reviva committed to closely collaborating with the FDA to secure the necessary data to support a potential NDA, reflecting its dedication to addressing unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVPH
Wall Street analysts forecast RVPH stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.256
Low
1.50
Averages
5.10
High
16.00
Current: 0.256
Low
1.50
Averages
5.10
High
16.00
About RVPH
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reviva Pharmaceuticals CEO to Present at Neuroscience Innovation Forum in San Francisco
- Forum Presentation: Reviva Pharmaceuticals' Founder and CEO Laxminarayan Bhat, Ph.D., will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, showcasing the company's advancements in CNS, inflammatory, and cardiometabolic diseases.
- Pipeline Focus: Reviva's current pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house, aimed at addressing unmet medical needs, which is crucial for societal and patient welfare.
- Patent Protection: The company has secured composition of matter patents for both brilaroxazine and RP1208 in the U.S., Europe, and several other countries, establishing a legal foundation for future commercialization and enhancing its competitive position in the market.
- Company Positioning: As a late-stage biopharmaceutical firm, Reviva is committed to developing next-generation therapeutics for CNS and other significant diseases, highlighting its strategic importance in the biopharmaceutical sector.
See More
Reviva Pharmaceuticals CEO to Present at 9th Annual Neuroscience Innovation Forum
- Key Presentation Scheduled: Reviva Pharmaceuticals' Founder and CEO, Dr. Laxminarayan Bhat, will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, showcasing the company's latest advancements in CNS and other disease areas.
- Focus on Unmet Medical Needs: Reviva is dedicated to developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, with its pipeline currently featuring two new chemical entities, brilaroxazine (RP5063) and RP1208, aimed at addressing significant health challenges faced by society and patients.
- Patent Protection Advantage: Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the U.S., Europe, and several other countries, which not only safeguards its innovative products but also lays a legal foundation for future commercialization efforts.
- Enhancing Industry Influence: By presenting at a key industry forum, Reviva aims to elevate its visibility in the biopharmaceutical sector, attracting potential investors and partners to accelerate the development and market introduction of its products.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Reviva Pharmaceuticals Initiates Second Phase 3 Trial RECOVER-2, Delaying NDA Submission to 2027
- Regulatory Requirement: The FDA has recommended that Reviva initiate the second Phase 3 trial, RECOVER-2, before submitting a New Drug Application, which will delay the filing timeline to 2027 as it aims to enroll approximately 790 patients to expand efficacy data and strengthen long-term safety evidence.
- Drug Development Progress: Brilaroxazine, Reviva's lead candidate, is designed to address both positive and negative symptoms of schizophrenia and has shown a favorable safety profile in over 900 subjects, indicating its potential competitiveness in the treatment landscape.
- Clinical Trial Results: Results from the completed RECOVER Phase 3 trial demonstrated statistically significant improvements in the Positive and Negative Syndrome Scale total score, with sustained efficacy observed in a one-year open-label extension, underscoring the clinical value of the drug.
- Market Reaction: Reviva's stock has traded between $0.25 and $2.17 over the past year, closing at $0.32, down 45.54% from the previous day, reflecting negative market sentiment regarding the FDA's delay.
See More
Reviva Pharmaceuticals Shares Plunge 45.9%, Dragging Down Drug Sector
- Market Underperformance: The pharmaceutical sector declines approximately 1.6%, with Reviva Pharmaceuticals' shares plummeting 45.9%, which may undermine investor confidence in the industry and impact future financing and R&D capabilities.
- Significant Individual Stock Impact: NovaBay Pharmaceuticals also sees a 19.1% drop, exacerbating negative sentiment towards the pharmaceutical sector, potentially putting pressure on the stock prices of other related companies and affecting overall industry valuations.
- Investor Reaction: The substantial declines in Reviva and NovaBay may lead to a cautious investment sentiment towards the pharmaceutical sector, impacting capital inflows and the industry's growth prospects.
- Uncertain Industry Outlook: With the ongoing slump in pharmaceutical stocks, companies within the sector may face greater financing challenges, affecting new drug development and competitive positioning in the market.
See More
Dow Jones Index Gains Over 100 Points as Durable Goods Orders Decline 2.2%
- Dow Jones Index Rise: The Dow Jones index increased by over 100 points on Tuesday, closing at 48,469.41, indicating a moderate market recovery despite disappointing economic data.
- Durable Goods Orders Decline: U.S. durable goods orders fell by 2.2% month-over-month to $307.4 billion in October, significantly missing market expectations of a 1.5% decline, reflecting weak manufacturing demand that could impact future economic growth.
- Accelerated GDP Growth: The U.S. GDP grew at an annualized rate of 4.3% in the third quarter, up from 3.8% in the previous quarter and exceeding market estimates of 3.3%, indicating potential for economic recovery that may positively influence the stock market.
- Mixed Sector Performance: Communication services rose by 0.5% while consumer staples fell by 0.5%, demonstrating varied market reactions across sectors, prompting investors to monitor industry dynamics for strategic adjustments.
See More
Reviva Pharmaceuticals CEO to Present at Neuroscience Innovation Forum in San Francisco
- Forum Presentation: Reviva Pharmaceuticals' Founder and CEO Laxminarayan Bhat, Ph.D., will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, showcasing the company's advancements in CNS, inflammatory, and cardiometabolic diseases.
- Pipeline Focus: Reviva's current pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house, aimed at addressing unmet medical needs, which is crucial for societal and patient welfare.
- Patent Protection: The company has secured composition of matter patents for both brilaroxazine and RP1208 in the U.S., Europe, and several other countries, establishing a legal foundation for future commercialization and enhancing its competitive position in the market.
- Company Positioning: As a late-stage biopharmaceutical firm, Reviva is committed to developing next-generation therapeutics for CNS and other significant diseases, highlighting its strategic importance in the biopharmaceutical sector.
See More
Reviva Pharmaceuticals CEO to Present at 9th Annual Neuroscience Innovation Forum
- Key Presentation Scheduled: Reviva Pharmaceuticals' Founder and CEO, Dr. Laxminarayan Bhat, will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, showcasing the company's latest advancements in CNS and other disease areas.
- Focus on Unmet Medical Needs: Reviva is dedicated to developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, with its pipeline currently featuring two new chemical entities, brilaroxazine (RP5063) and RP1208, aimed at addressing significant health challenges faced by society and patients.
- Patent Protection Advantage: Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the U.S., Europe, and several other countries, which not only safeguards its innovative products but also lays a legal foundation for future commercialization efforts.
- Enhancing Industry Influence: By presenting at a key industry forum, Reviva aims to elevate its visibility in the biopharmaceutical sector, attracting potential investors and partners to accelerate the development and market introduction of its products.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Reviva Pharmaceuticals Initiates Second Phase 3 Trial RECOVER-2, Delaying NDA Submission to 2027
- Regulatory Requirement: The FDA has recommended that Reviva initiate the second Phase 3 trial, RECOVER-2, before submitting a New Drug Application, which will delay the filing timeline to 2027 as it aims to enroll approximately 790 patients to expand efficacy data and strengthen long-term safety evidence.
- Drug Development Progress: Brilaroxazine, Reviva's lead candidate, is designed to address both positive and negative symptoms of schizophrenia and has shown a favorable safety profile in over 900 subjects, indicating its potential competitiveness in the treatment landscape.
- Clinical Trial Results: Results from the completed RECOVER Phase 3 trial demonstrated statistically significant improvements in the Positive and Negative Syndrome Scale total score, with sustained efficacy observed in a one-year open-label extension, underscoring the clinical value of the drug.
- Market Reaction: Reviva's stock has traded between $0.25 and $2.17 over the past year, closing at $0.32, down 45.54% from the previous day, reflecting negative market sentiment regarding the FDA's delay.
See More
Reviva Pharmaceuticals Shares Plunge 45.9%, Dragging Down Drug Sector
- Market Underperformance: The pharmaceutical sector declines approximately 1.6%, with Reviva Pharmaceuticals' shares plummeting 45.9%, which may undermine investor confidence in the industry and impact future financing and R&D capabilities.
- Significant Individual Stock Impact: NovaBay Pharmaceuticals also sees a 19.1% drop, exacerbating negative sentiment towards the pharmaceutical sector, potentially putting pressure on the stock prices of other related companies and affecting overall industry valuations.
- Investor Reaction: The substantial declines in Reviva and NovaBay may lead to a cautious investment sentiment towards the pharmaceutical sector, impacting capital inflows and the industry's growth prospects.
- Uncertain Industry Outlook: With the ongoing slump in pharmaceutical stocks, companies within the sector may face greater financing challenges, affecting new drug development and competitive positioning in the market.
See More
Dow Jones Index Gains Over 100 Points as Durable Goods Orders Decline 2.2%
- Dow Jones Index Rise: The Dow Jones index increased by over 100 points on Tuesday, closing at 48,469.41, indicating a moderate market recovery despite disappointing economic data.
- Durable Goods Orders Decline: U.S. durable goods orders fell by 2.2% month-over-month to $307.4 billion in October, significantly missing market expectations of a 1.5% decline, reflecting weak manufacturing demand that could impact future economic growth.
- Accelerated GDP Growth: The U.S. GDP grew at an annualized rate of 4.3% in the third quarter, up from 3.8% in the previous quarter and exceeding market estimates of 3.3%, indicating potential for economic recovery that may positively influence the stock market.
- Mixed Sector Performance: Communication services rose by 0.5% while consumer staples fell by 0.5%, demonstrating varied market reactions across sectors, prompting investors to monitor industry dynamics for strategic adjustments.
See More
